Loading…

Almirall SAALM.MCCompetitor analysis, valuation and peers

Spain · EUR·Health Care›Pharmaceuticals: Major

Spanish pharmaceutical company focused on medical dermatology drugs, sold mainly in Europe and the US.

≈ A smaller, dermatology-focused specialty pharmaMomentum weak 37
Mkt cap
$2.46B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$1.78M
20-day average traded
Fwd P/E
27.1×
forward earnings
ROIC−WACC
-1.3 pp
WACC 6.2%
Hurdle
-0 pp
Req g minus delivered
Official | Implied
BB+ / A-
agencies · bond market
Next earnings
96 days
22 Feb 2027
Close · EUR€10.32
1D-1.7%
1W-4.3%
1M-0.2%
3M-1.3%
6M-12.8%
YTD-19.6%
1Y-17.3%
ATR %2.8%
52w lowhigh26.2% off high

What Almirall does

Spanish pharmaceutical company focused on medical dermatology drugs, sold mainly in Europe and the US.

Sells prescription skin drugs through its own sales teams, with Europe the larger base. Much of the range is licensed in from others, such as Ebglyss, an eczema antibody it sells in Europe under licence from Eli Lilly, so partners take a share. It refocused on dermatology after selling its respiratory business to AstraZeneca in 2014.

In one line: A smaller, dermatology-focused specialty pharma.

Products and services

  • Prescription dermatology drugs
  • Actinic keratosis/psoriasis treatments
  • Skin cancer treatments

Customers

  • Dermatologists
  • Hospitals
  • Patients

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Dermatology drug development + sales

What could go right

  • Dermatology drug pipeline launches
  • US market expansion

What could go wrong

  • Patent cliffs / generic competition
  • Pricing pressure in European markets

Moat: narrow (IP / patents, regulatory licence). Patented dermatology drugs give temporary pricing power, eroding once generics enter.

Headquarters: Barcelona, Spain · Founded: 1943 · Employees: 2,108

Named competitors

Almirall at a glance

Size Almirall (ALM.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $2.46B, the 45th largest of 93 Spain companies the cockpit tracks. Shares closed at €10.32 on 18 Nov 2026.

Performance Over six months the shares fell 12.8%, against -8.4% for the median peer and +5.3% for the Spain market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 24.3% over the last twelve months (peer median +0.1%); the operating margin is 8.4% (peer median 10.6%).

Valuation It trades at 27.1× forward earnings against a peer median of 26.5× (8th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.3 points below its cost of capital (6.2% WACC).

Credit Almirall has 1 bond outstanding ($277M), rated BB+ by the agencies and trading like A- at a weighted spread of 95 bp.

Next results Next results expected around 22 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 90ALM.MC 89
Six months, rebased to 100: Almirall against the median of its 20 peers (local-currency closes).

Almirall financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.15B€1.11B€986M€895M€863M
Revenue growth—+12%+10%+4%—
Gross profit€490M€457M€394M€349M€359M
EBITDA€246M€219M€185M€164M€174M
Net income€59.1M€46.2M€10.1M-€38.5M€4.28M
Free cash flow€209M€134M€127M€54.9M€122M
Capital expenditure€153M€137M€161M€159M€116M
Total debt€321M€325M€390M€397M€400M

Quarterly statements and history in the cockpit →

Almirall competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%301301PBH369621620013IDYANAMS000250PRGO600518RGC301080BIOA-B300199603858APLLTD600267600380ALM.MC6-month return →1-month return →
Up and to the right = strong over both horizons. Almirall is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×301301PBH369621620013PRGO301080BIOA-B300199300558APLLTD600267ALM.MCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Almirall is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%301301PBH36960013PRGO301080BIOA-B300199603858300558600267600380ALM.MCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Almirall is the large dot.

Almirall competitors and peer comparison

Head to head with its named competitors (ALM.MC vs GALD.SW vs BHC.TO vs SUNPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Almirall ALM.MC$2.46B-13%+24%8%27.1×6.1%
Galderma GALD.SW$51.9B+18%+16%19%45.7×18.0%
Bausch Health Companies BHC.TO$3.27B+66%+10%27%2.0×-14.8%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Incyte INCY$24.0B+21%+25%12%15.1×14.2%
Arcutis Biotherapeutics ARQT$3.49B+35%+60%7%41.0×49.2%
Organon & OGN$3.66B+3%-3%20%4.0×-4.1%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%

How Almirall compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Almirall against its 20 peers (data as of 18 Nov 2026)
MeasureALM.MCPeer medianRank in peer set
1-month return-0.2%-5.5%8th highest of 21
6-month return-12.8%-8.4%8th lowest of 21
Distance from 52-week high-26.2%-28.5%10th highest of 21
Revenue growth (TTM)+24.3%+0.1%4th highest of 20
Operating margin8.4%10.6%9th lowest of 19
Forward P/E27.1×26.5×8th cheapest of 15
Growth the price implies (Req g, 7 yrs)6.1%18.7%7th least demanding of 15
Growth delivered (Del g)+6.5%+5.5%6th highest of 15
Hurdle (Req g minus delivered)-0.5 pp+6.3 pp6th least demanding of 15
ROIC minus cost of capital-1.3 pp-2.1 pp8th highest of 15
EV / EBITDA9.0×13.7×2nd cheapest of 4
Net debt / EBITDA-0.1×2.9×2nd least indebted of 5
Bond spread95 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%

Almirall bonds and credit

Almirall has 1 bond outstanding with $277M face value. The agencies rate it BB+; its bonds trade like A-. Weighted yield 4.36%, a spread of 95 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Almirall's main competitors?
Named competitors: Galderma (GALD.SW), LEO Pharma (private) (private or unlisted), Bausch Health (BHC.TO), Sun Pharma (SUNPHARMA.NS), Incyte (INCY), Arcutis Biotherapeutics (ARQT). The cockpit's measured peer set (industry) also includes Yili Chuanning Biotechnology (301301.SZ), Prestige Consumer Healthcare (PBH), InSilico Medicine Cayman TopCo (3696.HK), Keymed Biosciences (2162.HK), HUTCHMED (China) (0013.HK), IDEAYA Biosciences (IDYA).
Is Almirall expensive compared with its peers?
On forward p/e it trades at 27.1× against a peer median of 26.5×, 8th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Almirall stock performed?
Over six months to 18 Nov 2026 the shares returned -12.8% against -8.4% for the median peer; over one year -17.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.